Narazaciclib, a Differentiated CDK4/6 Antagonist, Prolongs Cell Cycle Arrest and Metabolomic Reprogramming, Enabling Restoration of Ibrutinib Sensitivity in Btki-Resistant Mantle Cell Lymphoma
Núria Profitós-Pelejà, Marcelo Lima Ribeiro, Jeronimo Parra, Miranda Fernández-Serrano, Pau Marin-Escudero, Joan Josep Bech, Carolina de la Torre, Adar Makovski Silverstein, Steve Cosenza, Steven Fruchtman, Manel Esteller, Gaël Roué (2023). Narazaciclib, a Differentiated CDK4/6 Antagonist, Prolongs Cell Cycle Arrest and Metabolomic Reprogramming, Enabling Restoration of Ibrutinib Sensitivity in Btki-Resistant Mantle Cell Lymphoma. , 142(Supplement 1), DOI: https://doi.org/10.1182/blood-2023-189838.
